Cargando…
Short-course Rifaximin therapy efficacy and lactulose hydrogen breath test in Chinese patients with diarrhea-predominant irritable bowel syndrome
BACKGROUND: Gut microbiota alterations including small intestinal bacterial overgrowth (SIBO) might play a role in pathogenesis of irritable bowel syndrome (IBS). Rifaximin could effectively and safely improve IBS symptoms. The aim of this study was to investigate the effect of rifaximin on Gastroin...
Autores principales: | Zhuang, Xiaojun, Tian, Zhenyi, Luo, Mei, Xiong, Lishou |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7291629/ https://www.ncbi.nlm.nih.gov/pubmed/32532214 http://dx.doi.org/10.1186/s12876-020-01336-6 |
Ejemplares similares
-
Fecal Microbiota Alterations Associated With Diarrhea-Predominant Irritable Bowel Syndrome
por: Zhuang, Xiaojun, et al.
Publicado: (2018) -
Lactulose Breath Testing as a Predictor of Response to Rifaximin in Patients With Irritable Bowel Syndrome With Diarrhea
por: Rezaie, Ali, et al.
Publicado: (2019) -
The propionic acid and butyric acid in serum but not in feces are increased in patients with diarrhea-predominant irritable bowel syndrome
por: Tian, Zhenyi, et al.
Publicado: (2020) -
Short-course therapy for diarrhea-predominant irritable bowel syndrome: understanding the mechanism, impact on gut microbiota, and safety and tolerability of rifaximin
por: Chang, Christopher
Publicado: (2018) -
Determination of Rifaximin Treatment Period According to Lactulose Breath Test Values in Nonconstipated Irritable Bowel Syndrome Subjects
por: Bae, Suhyun, et al.
Publicado: (2015)